OmniAb (OABI) Net Income towards Common Stockholders (2021 - 2026)

OmniAb's (OABI) quarterly Net Income towards Common Stockholders came in at -$7.7 million in Q1 2026, up 57.65% year-on-year from -$4.9 million in Q1 2025, and up 45.64% on a QoQ basis from -$14.2 million in Q4 2025.

OmniAb (OABI) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends

OmniAb (OABI) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$7.7 million in Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 57.65% year-over-year to -$7.7 million in Q1 2026; TTM through Mar 2026 was -$54.3 million, a 11.4% increase from a year earlier, with the FY2025 full-year figure at -$64.8 million, down 4.43% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$7.7 million, up from -$14.2 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for OABI reached as high as $6.8 million in Q4 2022 and fell as low as -$19.0 million in Q1 2024.
  • Historically, Net Income towards Common Stockholders has averaged -$10.9 million across 5 years, with a median of -$14.1 million in 2023.
  • On a YoY basis, Net Income towards Common Stockholders climbed as much as 7322.66% in 2022 and fell as far as 59393.5% in 2022.
  • Year by year, Net Income towards Common Stockholders stood at $6.8 million in 2022, then sank by 306.06% to -$14.1 million in 2023, then climbed by 7.01% to -$13.1 million in 2024, then declined by 8.5% to -$14.2 million in 2025, then surged by 45.64% to -$7.7 million in 2026.
  • Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$7.7 million in Q1 2026, -$14.2 million in Q4 2025, and -$16.5 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -625.73
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -0.68
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 472.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - -453.82 Mn
10 OmniAb 260.98 Mn 211.91 Mn 14.41 Mn -7.71 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -7.71 Mn
Dec 31, 2025 -14.18 Mn
Sep 30, 2025 -16.53 Mn
Jun 30, 2025 -15.88 Mn
Mar 31, 2025 -18.20 Mn
Dec 31, 2024 -13.07 Mn
Sep 30, 2024 -16.37 Mn
Jun 30, 2024 -13.63 Mn
Mar 31, 2024 -18.96 Mn
Dec 31, 2023 -14.05 Mn
Sep 30, 2023 -15.74 Mn
Jun 30, 2023 -14.73 Mn
Mar 31, 2023 -6.10 Mn
Dec 31, 2022 6.82 Mn
Sep 30, 2022 -1.97 Mn
Jun 30, 2022 -1.30 Mn
Mar 31, 2022 -3.67 Mn
Dec 31, 2021 -94,425.00
Sep 30, 2021 -52,185.00
Jun 30, 2021 -2,185.00